Jade Biosciences, Inc. has announced the completion of its merger with Aerovate, resulting in the formation of a new entity named the Combined Company. This merger involved the integration of Jade Biosciences, LLC into Jade Biosciences, Inc., and the newly formed entity will continue under the name Jade Biosciences, Inc. Led by Jade's pre-merger management team, the Combined Company will focus on developing innovative biologic therapies for autoimmune diseases. The merger reflects Jade Biosciences' strategy to enhance its development capabilities and expand its portfolio in the biotech industry.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jade Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-119856), on May 14, 2025, and is solely responsible for the information contained therein.